Hemophilia prevalence in Azerbaijan

Cover Page

Cite item


Aim. Assessment of hemophilia prevalence in Azerbaijan.

Methods. Materials of the study were the data of the registry on hemophilia. Prevalence and its structure were calculated for the regions and towns of republican subordination: the number of hemophilia patients with all types were calculated per 100 000 people. We determined the following groups: 0-4, 5-13, 14-18, 19-44, 45 years and older. According to clinical forms of the pathology we differentiated hemophilia А, hemophilia В, Willebrand’s disease and other forms. According to severity the patients were divided into 3 groups: severe with factors VIII and IX activity less than 1%, moderate - 2-5%, and mild - 5% and higher.

Results. Hemophilia prevalence in Azerbaijan Republic is 17.2±0.44 per 100 000 people. Baku is leading, where it is 33.1±1.22 hemophilia cases per 100 000 people. Relatively high prevalence rate was recorded in Sumgait city (22.8±2.61 per 100 000 people). Among hemophilia patients a male predominance is observed (1323 people, 87.2% of all patients). In all age groups hemophilia A is predominant and ratios of hemophilia B, Willebrand’s disease and other forms are significantly lower. Mild form of hemophilia was registered most often. Proportion of patients with severe hemophilia was lowest in the group with Willebrand’s disease (13%) and highest in the group with other hemophilia types (46.6%).

Conclusion. Hemophilia prevalence in Azerbaijan is high (17.2±0.44 per 100 000 people) and regional and age distribution differences are clearly pronounced; in nosological structure hemophilia A and other forms are predominant, nevertheless every fifth patients has severe form of the pathology.

About the authors

M M Kazimova

Azerbaijan state institute of doctors’ improvement named after A. Aliyev; Central hospital of Kel’badzharskiy region

Author for correspondence.
Email: agayevakamala@mail.ru

E A Kadimova

Azerbaijan state institute of doctors’ improvement named after A. Aliyev

Email: agayevakamala@mail.ru


  1. Дашкевич Э.В., Ольковик Ю.В., Рудб М.С. и др. Анализ распространённости гемофилии в республике Беларусь. Мед. новости. 2014; (9): 29-30.
  2. Кудрявцева Л.М., Плющ О.П., Копылов К.Г. и др. Характеристики алгоритмов гемостатической терапии гемофилии. Пробл. гематол. и переливание крови. 2006; (2): 41-46.
  3. Полянская Т.Ю. Современные представления о патогенезе, профилактике и лечении гемофилии, осложнённой развитием ингибитора. Гематол. и трансфузиол. 2002; (3): 38-42.
  4. Стентон Г. Медико-биологическая статистика. М.: Практика. 1999; 459 с.
  5. Canadian Hemophilia Registry. http://www.fhs.memaster./ca/chr/ (access date: 01.02.2014).
  6. Sackson S.C., Yang M., Minuk Z. et al. Prophylaxis in order Canadian adults with hemophilia A: lessons and more questions. BMC Hemothology. 2015; 15: 4. doi: 10.1186/s12878-015-0022-8
  7. Petkova R., Chakarov S., Kremensky I. Genetic analysis of hemophilia A in Bulgaria. BMC Blood Disord. 2004; 4: 2.

© 2017 Kazimova M.M., Kadimova E.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies